# A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

> **NCT05256810** · PHASE1,PHASE2 · TERMINATED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** ALN-XDH
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05256810
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-25
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-01-25
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** The Sponsor elected not to continue with the study
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256810, "A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05256810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*